Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112186 · ClinicalTrials.gov registry record · NA
Mindfulness-Oriented Recovery Enhancement (MORE) in Heroin Addiction
A NA study of Opiate Use Disorder, sponsored by Icahn School of Medicine at Mount Sinai.
- Active
- Registry status
- NA
- Development phase
- 157
- Enrollment target
- 1
- Study location
NCT04112186: Active NA study of Opiate Use Disorder, sponsored by Icahn School of Medicine at Mount Sinai.
NCT04112186 is a NA study of Opiate Use Disorder that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 157 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04112186, a NA study of Opiate Use Disorder, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 157 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, neuroimaging of reward processing, drug cue reactivity and inhibitory control is used before and immediately after 8 weeks of two types of group therapy in individuals with opioid addiction; clinical outcomes will be assessed before, immediately and three months after treatment. Results could point to factors that track and predict recovery with treatment, offering clinicians markers that can be used for enhancing precision medicine with the goal of reducing morbidity and mortality associated with opiate addiction.
Primary Outcome
Change in fMRI blood-oxygen-level dependent (BOLD) signal acquired during tasks of reward at the 2nd MRI conducted immediately after the 8-week group therapy (about 3 months after enrollment) as compared to baseline MRI. The reward task uses symbols of gain/win and has been shown to elicit BOLD activations in the brain's reward network.
Conditions Studied
Interventions
- BEHAVIORAL Behavioral group therapy #1
- BEHAVIORAL Behavioral group therapy #2
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2020-06-21 |
| Est. Completion | 2031-03-31 |
| Phase | NA |
What the registry record for NCT04112186 still lists
NCT04112186 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Opiate Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Behavioral group therapy #1 is the first listed.
NCT04112186 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04112186 about?
NCT04112186 is a clinical study titled "Mindfulness-Oriented Recovery Enhancement (MORE) in Heroin Addiction". In this study, neuroimaging of reward processing, drug cue reactivity and inhibitory control is used before and immediately after 8 weeks of two types of group therapy in individuals with opioid addiction; clinical outcomes will be assessed before, immediately and three months after treatment. Resul...
What is the current status of trial NCT04112186?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 157 participants. The study started on 2020-06-21. Estimated completion is 2031-03-31.
What conditions does trial NCT04112186 study?
This clinical trial studies the following conditions: Opiate Use Disorder.
What interventions are being tested in trial NCT04112186?
The interventions under investigation include: Behavioral group therapy #1 (BEHAVIORAL), Behavioral group therapy #2 (BEHAVIORAL).
Who is sponsoring clinical trial NCT04112186?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04112186 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04112186's enrollment target sits among peer trials
157 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI